CureVac NV - EUR 400 Mln Upfront Payment From Restructured GSK Collaboration Reflected in Financials, Cash Position Increased to EUR 551 Mln; Expected Cash Runway Re-Affirmed Into 2028
CureVac NV - 4億歐元的預付款反映在財務報表中,現金頭寸增至5.51億歐元;預期現金運營至2028年再次確認
CureVac NV - EUR 400 Mln Upfront Payment From Restructured GSK Collaboration Reflected in Financials, Cash Position Increased to EUR 551 Mln; Expected Cash Runway Re-Affirmed Into 2028
CureVac NV - 4億歐元的預付款反映在財務報表中,現金頭寸增至5.51億歐元;預期現金運營至2028年再次確認
譯文內容由第三人軟體翻譯。